Related references
Note: Only part of the references are listed.Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias
Jorge E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
Jorge E. Cortes et al.
BLOOD (2011)
Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance
Tianjun Zhou et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2011)
Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy Participants
Chiaki Tanaka et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Effect of Ketoconazole on the Pharmacokinetics of Oral Bosutinib in Healthy Subjects
Richat Abbas et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Phase 1 Pharmacokinetic and Drug-Interaction Study of Dasatinib in Patients With Advanced Solid Tumors
Faye M. Johnson et al.
CANCER (2010)
Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant
Wei-Sheng Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Thomas O'Hare et al.
BLOOD (2007)
Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole
Jenny Y. Chien et al.
DRUG METABOLISM AND DISPOSITION (2006)
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
E. Weisberg et al.
BRITISH JOURNAL OF CANCER (2006)
The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants
John S. Tokarski et al.
CANCER RESEARCH (2006)
Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects
C Dutreix et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Effects of the antifungal agents on oxidative drug metabolism - Clinical relevance
K Venkatakrishnan et al.
CLINICAL PHARMACOKINETICS (2000)
Share Paper
